ECS Botanics Holdings Ltd (ASX:ECS)
Australia · Delayed Price · Currency is AUD 0.0080
0.00 (0.00%)
Oct 24, 2025, 11:20 AM AEST
ECS Botanics Holdings Revenue
In the fiscal year ending June 30, 2025, ECS Botanics Holdings had annual revenue of 19.36M AUD, down -3.33%. ECS Botanics Holdings had revenue of 9.63M in the half year ending June 30, 2025, with 12.16% growth.
Revenue
19.36M
Revenue Growth
-3.33%
P/S Ratio
0.54
Revenue / Employee
n/a
Employees
n/a
Market Cap
10.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 19.36M | -667.21K | -3.33% |
| Jun 30, 2024 | 20.03M | 4.64M | 30.16% |
| Jun 30, 2023 | 15.39M | 10.09M | 190.43% |
| Jun 30, 2022 | 5.30M | 3.92M | 285.34% |
| Jun 30, 2021 | 1.38M | 455.92K | 49.60% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Ramsay Health Care | 17.79B |
| Sonic Healthcare | 9.65B |
| Ansell | 3.06B |
| Cochlear | 2.34B |
| Regis Healthcare | 1.16B |
| Telix Pharmaceuticals | 1.01B |
| Neuren Pharmaceuticals | 218.86M |